CDKN2B is critical for verapamil-mediated reversal of doxorubicin resistance in hepatocellular carcinoma

Tengyue Zhang; Kelong Ma; Jin Huang; Shitang Wang; Yabei Liu; Gaofei Fan; Miao Liu; Guangshan Yang; Cheng Wang; Pingsheng Fan

doi:10.18632/oncotarget.22123

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

CDKN2B is critical for verapamil-mediated reversal of doxorubicin resistance in hepatocellular carcinoma

Tengyue Zhang, Kelong Ma, Jin Huang, Shitang Wang, Yabei Liu, Gaofei Fan, Miao Liu, Guangshan Yang, Cheng Wang and Pingsheng Fan _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:110052-110063. https://doi.org/10.18632/oncotarget.22123

Metrics: PDF 1562 views | HTML 3042 views | ?

Abstract

Tengyue Zhang1,2,*, Kelong Ma3,*, Jin Huang2,*, Shitang Wang4,*, Yabei Liu2, Gaofei Fan2, Miao Liu2, Guangshan Yang2, Cheng Wang4 and Pingsheng Fan1,2

1School of Clinical Medicine, Shan Dong University, Jinan 250100, China

2The Cancer Hospital of Anhui Province, Provincial Hospital of Anhui Medical University, Hefei 230032, China

3Clinical College of Integrated Traditional Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei 230032, China

4Department of General Surgery, Provincial Hospital of Anhui Medical University, Hefei 230032, China

*These authors have contributed equally to this work

Correspondence to:

Pingsheng Fan, email: [email protected]

Cheng Wang, email: [email protected]

Keywords: hepatocellular carcinoma (HCC); verapamil (VER); doxorubicin (ADM); CDKN2B; chemotherapy resistance

Received: June 14, 2017 Accepted: October 05, 2017 Published: October 26, 2017

ABSTRACT

In this study, we explored the function and mechanism of CDKN2B genes in verapamil (VER)-induced reversal of resistance to doxorubicin (ADM) chemotherapy in hepatocellular carcinoma (HCC). We examined 4 HCC cell lines and found that the expression levels of CDKN2B genes correlated with the level of apoptosis induced by ADM+VER. Overexpression of CDKN2B genes promoted apoptosis in cells treated with VER+ADM. CDKN2B knockdown using siRNA weakened the effect of ADM+VER, indicating that ADM+VER promotes HCC cell apoptosis and that CDKN2B genes participate in VER-mediated promotion in tumor cell apoptosis. Future research will further explore the functional mechanism, and the associated signal transduction pathways via which CDKN2B affects HCC drug resistance.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22123

Publication Alerts

Oncoscience

Post-Publication Promotion

Research Papers:

CDKN2B is critical for verapamil-mediated reversal of doxorubicin resistance in hepatocellular carcinoma

Abstract